STATEMENT OF NEED
Hematopoietic stem cell transplant (HSCT) is a potentially curative therapy for patients with hematologic malignancies. There are 2 primary types of HSCT: autologous, where the cells are taken from the patient, and allogeneic, where the cells come from a matched sibling donor or an unrelated donor. Advances in HSCT include the introduction of reduced-intensity conditioning regimens that allow transplant in older patients and alternative graft sources that afford a donor for nearly all patients who require a transplant. Despite these advances, studies continue to show that the use of HSCT remains suboptimal, placing many patients at increased risk for poor survival outcomes.
Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients eligible for HSCT.
Upon completion of this activity, participants should be able to:
Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians.
Miguel-Angel Perales, MD (Chairperson)
Deputy Chief, Adult Bone Marrow Transplantation Service
Memorial Sloan Kettering Cancer Center
Corey S. Cutler, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Mark A. Schroeder, MD
Associate Professor of Medicine
Washington University Medical School
Daniel Weisdorf, MD
Professor of Medicine
University of Minnesota
There is no fee to participate in or claim CME/CE credit for this activity.
Please note that i3 Health does not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
i3 Health is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
i3 Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hour of Category 1 credit for completing this program.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Continuing Nursing Education
i3 Health is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.0 contact hour may be earned by learners who successfully complete this continuing nursing education activity. This activity has been designated for 0.3 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 contact hour.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1 ILNA point toward:
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CME/CE content about products or services of a commercial interest with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health will identify, review, and resolve all conflicts of interest that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.
Relevant financial relationships exist between the following individuals and commercial interests:
The i3 Health planners, reviewers, and managers have nothing to disclose.
Miguel-Angel Perales, MD discloses that he has served as a consultant/advisor for Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, MolMed, Nektar Therapeutics, NexImmune, Novartis, and Takeda.
Corey S. Cutler, MD, MPH discloses that he has served as a consultant/advisor for Bristol-Myers Squibb, Genentech, Incyte, Jazz, Kadmon, Pfizer, and Pharmacyclics.
Mark A. Schroeder, MD discloses that he has served on the speakers' bureau for Abbvie, Merck, and Takeda. He has also served on the advisory boad for Amgen, Astellas, Flatiron, Incyte, Partners Therapeutics, Pfizer, and Sanofi. Dr. Schroeder has received research support from Amgen, Celgene, Incyte, Janssen, PBD Inc, Pfizer, and Sanofi.
Daniel Weisdorf, MD, discloses that he has served as a consultant for FATE and Pharmacyclics. He has also received research support from Incyte.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME/CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by independent educational grants from Sanofi Genzyme and Incyte.
Aggregate participant data will be shared with commercial supporters of this activity.
AMERICANS WITH DISABILITIES ACT